Editorial: Ovarian cancer-targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more

• Zhi-Bin Wang,
• Zhi-Bin Wang,
• Dan Liu,
• Guang Lei,
• Zhao-Qian Liu,
• Zhao-Qian Liu,
• Nayiyuan Wu,
• Nayiyuan Wu,
• Jing Wang,
• Jing Wang

Affiliations

Zhi-Bin Wang

Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China

Zhi-Bin Wang

Public Service Platform of Tumor Organoids Technology, Hunan Gynecological Tumor Clinical Research Center, Changsha, Hunan, China

Dan Liu

Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Guang Lei

Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Zhao-Qian Liu

Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China

Zhao-Qian Liu

Institute of Clinical Pharmacology, Engineering Research Center for applied Technology of Pharmacogenomics of Ministry of Education, Central South University, Changsha, Hunan, China

Nayiyuan Wu

Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China

Nayiyuan Wu

Public Service Platform of Tumor Organoids Technology, Hunan Gynecological Tumor Clinical Research Center, Changsha, Hunan, China

Jing Wang

Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China

Jing Wang

Public Service Platform of Tumor Organoids Technology, Hunan Gynecological Tumor Clinical Research Center, Changsha, Hunan, China